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Introduction
Monoclonal antibodies are widely used immunological tool with 
therapeutic, research, and also diagnostic applications because of high 
specificity and affinity against their antigens [1]. A variety of well-
established techniques such as hybridoma, phage, and other associated 
display approaches, have been employed to develop numerous novel 
antibodies against potential targets [2,3]. Antibody engineering 
approaches are often necessary to optimize physicochemical 
characteristics of the bio-therapeutic agents regarding to clinical 
progress and industrial production. Various properties that potentially 
require to be improved are including specificity, affinity, stability, 
solubility, lack of aggregation, solubility, etc. [4]. Antibodies acquire 
their affinity and specificity towards a variety of target antigens by 
modifying amino acid residues within their six CDRs, three from 
heavy chain (CDR-H1, CDR-H2, CDR-H3) and three from light 
chain (CDR-L1, CDR-L2, CDR-L3) which known as hypervariable 
regions [5]. The molecules precisely recognize epitopes of varying size 
using only a limited number of amino acid residues in their CDRs [6]. 
Recently, complicates experimental and computational efforts have 
occurred to engineer the CDRs compositions and achieve therapeutic 
antibodies that recognize its antigen with higher affinity and specificity 
[7]. In most cases, an increase in the binding activity and affinity of 
antibody enhanced the biological activity and decreased the dose of 
requirements, lead to improved efficiency, lower side effects and costs.
Until now, various mutagenesis strategies have confirmed as 
useful methods to increase the affinity of antibodies by substitution 
of particularly selected residues in the CDR loops or by random 
mutagenesis in the variable fragment sequence [8,9]. Furthermore, 
several computational methods have been employed to improve affinity 
of different antibodies by using of rational insights into the CDR loops 
and reported that CDR-L3 and, especially, CDR-H3 are frequently 
responsible for greatest contacts between antibody-antigen [10-12].
TNFα is a multifunctional cytokine that play some crucial roles 
in regulating immune hematopoiesis and in developing inflammation 
diseases [13-15]. Accordingly, different anti-TNFα antibodies including 
etanercept, golimumab, infliximab, adalimumab and certolizumab, 
have been approved for treatment of several diseases such as rheumatoid 
arthritis, inflammatory bowel disease, and psoriasis [16,17]. D2E7, a 
full-humanized antibody, developed by phage display method and is 
extensively used with rheumatoid arthritis patients. Former studies 
have focused on to reduce side effects of the antibody that is in result 
of highly recommended dose in the patients. In the studies, D2E7 have 
been applied as a target for CDR engineering in order to improved 
affinity and biological activity [8,18].
In our research group, we have applied a set of bioinformatics 
analyses based on molecular dynamics simulations approaches that 
reported with other study [19] to produce D2E7 mutant models with 
an improved binding affinity and biological activity (data not shown). 
According to our data, three variant of D2E7 antibody with a single 
point mutation at their CDRs of light chain (lc-A94K, lc-N92R, lc-
A50Y), and a variant with a single point mutation at its CDR1 of heavy 
chain (hc-A33R) are potential models to be experimentally investigated 
in respect of increased affinity and potency.
In the present study, we aimed to evaluate binding affinity and 
biological activity of D2E7 antibody and the four candidate models 
against TNFα to find the best-optimized model with minimum 
structural modifications.
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Abstract
Rapid growth in the therapeutic antibody market leads to a drastic development of antibody engineering to optimize biophysical properties. 
One of the main focuses of biopharmaceutical researches was the expansion of different approaches for affinity maturation of antibodies to 
enhance biological activity. Adalimumab (D2E7) is an anti-tumor necrosis factor alpha (TNFα) antibody used in the treatment of some autoimmune 
disorders like rheumatoid arthritis, psoriasis, etc. In this study, by engineering complementary determining regions (CDRs) of D2E7 antibody, we 
produced a new variant of the antibody with improved affinity and potency to TNFα. We designed four D2E7 mutants that harbored a single point 
mutation in their CDRs. The native antibody, lc-A94K, lc-A50Y, lc-A33R, and lc-A92R mutant models were transiently produced and characterized. 
Data showed mutation of ALA to LYS in CDR3 of D2E7 antibody generated new hydrogen bonds with TNFα, thus the lc-A94K model revealed 
significantly higher binding activity (EC50) and kinetic affinity (KD) to its antigen, in comparison to the wild antibody. Moreover, this model was 
found to have significantly stronger biological activity (IC50) to activate antibody-dependent cell-mediated cytotoxicity in the mouse fibroblast L929 
cells. Secondary structure analysis demonstrated the mutation has no inappropriate conformational impact on the beta and alpha structures of 
lc-A94K antibody. In conclusion, our study revealed that it is possible to manipulate antibody’s CDRs to increase affinity and potency by single 
point mutation and also preserve basic structure of the original antibody during CDRs engineering to avoid adverse effects of CDRs mutations on 
specificity and stability.
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Methods
Expression vectors and cloning
DNA encoding the light and heavy chain of D2E7 antibody was codon 
optimized for antibody expression in mammalian cells. The expression 
vector pcDNA3.1 that containing D2E7 sequence was obtained from 
General Biosystem (USA). To prepare vectors expressing the mutant 
antibodies, we applied polymerase chain reaction (PCR) site-directed 
mutagenesis approach. Primers were used for the mutagenesis step are 
listed (Table 1). PCR was performed by using Pfu DNA polymerase with 
the following conditions: one cycle at 95°C for five minutes, followed 
by 18 cycles with 95°C for 50 seconds, 60°C for 50 seconds and 68°C 
for 9 minutes and at the end one cycle at 68°C for one minute. The 
PCR products were digested with 1 µl of Dpn1 enzyme (ThermoFisher, 
USA) and incubated for 10 minutes at 37°C. The mutated plasmids were 
transformed into competent cells of E. coli strain DH5α. The bacteria 
were grown overnight at 37°C on agar plates. Three single colonies were 
picked and expanded. Plasmids of each colonies were extracted using a 
Miniprep kit (ThermoFisher, USA) and sequenced (Microsynth, USA). 
To confirm mutagenesis, the purified plasmids were sequenced using 
3130 ABI sequencer.
Expression and purification of antibodies
Human embryonic kidney cells 293 (HEK293T) (ATCC, LGC 
Standards GmbH, Wesel, Germany: ATCC-No. CRL-11268) 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Thermofisher, USA) supplemented with 8% (v/v) heat inactivated fetal 
calf serum (FCS) (Gibco Sera, Thermo Fischer, USA) and 1% (v/v) of 
a 5.000 U/mL penicillin-streptomycin solution (Thermfisher, USA) at 
37°C, 5% CO2 and 95% humidity [20]. For transfection, HEK293T cells 
were seeded into 10 cm plates using 12.5 mL culture medium so that they 
reached 70-80% confluence after one day in culture. In the next step, 10 
μg polyethyleneimine (PEI) (Polysciences, USA), and 10 μg high quality 
purified plasmid were separately diluted in 600 μL DMEM medium. 
The DNA and PEI solutions were combined, mixed and incubated for 
15–30 minutes at room temperature (RT). The DNA/PEI mixtures were 
distributed over the HEK293T cells and incubated for 24 h at 37°C. 
Following day, the medium was completely replaced with DMEM 
medium that was supplemented with 1% penicillin/streptomycin and 
with 4% (v/v) of IgG stripped FCS (PAA) to minimize co-purification 
of bovine IgG. The medium was exchanged and harvested every day for 
up to one week and the expression of the antibody was monitored using 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) on a 12% polyacrylamide gel.
Protein-A affinity chromatography
Protein-A affinity purification was performed using 1 ml HiTrap 
MabSelect SuRe columns (GE Healthcare, USA) on an ÄKTA protein 
purification system (GE Healthcare, USA). This column is specified 
for the purification of monoclonal antibody based on their affinity 
for protein-A. The binding and wash buffers were as follows: 20mM 
sodium phosphate, 0.15 M NaCl (pH: 7.2). Elution buffer was 0.1M 
sodium citrate (pH: 3.0) and neutralization buffer was 1M Tris-HCl 
(pH: 9). Concentration of the antibodies was determined by optical 
density at 280 nm on an ultraviolet (UV)–light spectrophotometer 
(GE Healthcare, USA) using the extinction coefficient (EC) of the 
antibody. The purified antibodies were analyzed by SDS-PAGE on a 
12% polyacrylamide gel under reducing and non-reducing conditions.
Circular Dichroism (CD) measurement
CD spectroscopy was carried out on a JASCO J-810 spectrometer to 
compare the secondary structure of mutant and wild antibodies, at 0.125 
mg/ml, in the far-UV region (250–190 nm), at 25°C. Three consecutive 
scans were accumulated for each sample and the spectra obtained were 
averaged. The Mean residue ellipticity (MRE) was calculated according 
to the previous works [21] and the BESTSEL server [22].
Enzyme-Linked Immunosorbent Assay (ELISA) measurement
Binding activities of the native and mutant antibodies to 
recombinant human TNFα (Biolegend, USA) were determined by 
ELISA. First, 100 µl/well TNFα (1 µg/ml) in phosphate buffered saline 
(PBS, pH=7.2) was coated at a 96-well microtitre plate and incubated 
overnight at 4°C. After that, the wells were washed three times with PBS 
containing 0.05% Tween-20 (PBST) and blocked with blocking buffer 
(PBS containing 1% FCS) for 2 hr at RT. Following, the antibodies 
(diluted in PBS) were added to the wells in serial dilution, triplicates and 
then incubated for 2 hr at RT. The wells were washed four times with 
PBST. A total of 100 µl of horseradish peroxidase-conjugated Goat-
Anti-Human IgG (Abcam, USA) was added to each well and incubated 
for 1 hr at RT. After five washing steps by PBST, 100 µl of substrate 
3,3´,5,5´,-tetramethylbenzidine (TMB) (Biomol, Germany) was added 
as a substrate to the wells and the absorbance was read at 450 nm on a 
microplate reader.
Surface Plasmon Resonance (SPR) measurement
The kinetic affinity of the native and mutant antibodies to 
recombinant human TNFα was determined by SPR spectroscopy 
on a Biacore X100 (GE Healthcare, USA) instrument. The assay 
format was Fc-based capture via immobilized antibody. A ready to 
use carboxymethylated dextran (CM5) sensor chip was built up by a 
carboxymethylated dextran matrix with a recombinant protein-A 
variant that covalently attached to it. The chip eliminated needs for 
developing an immobilization procedure. In a first step, antibody (5 µg/
mL) was bound to this protein-A sensor chip (GE Healthcare, USA) 
with a flow rate of 10 μL/minute for 180 seconds to reach an optimum 
response unit (RU). Afterward, different concentrations of TNFα (200, 
19
Oligo Name Base Number Tm* (°C) Oligo Sequence
lc-A94K-P1 40 78 GCC TTG GCC GAA GGT GTA TGG TTT TCT GTT GTA TCT TTG G
lc-A94K-P2 40 78 CCA AAG ATA CAA CAG AAA ACC ATA CAC CTT CGG CCA AGG C
lc-N92R-P1 38 79 GGC CGA AGG TGT ATG GTG CTC TTC TGT ATC TTT GGC AG
lc-N92R-P2 38 79 CTG CCA AAG ATA CAG AAG AGC ACC ATA CAC CTT CGG CC
lc-A50Y-P1 35 79 CCG CTT TGC AGG GTA GAG GCG TAG TAG ATG AGG AG
lc-A50Y-P2 35 79 CTC CTC ATC TAC TAC GCC TCT ACC CTG CAA AGC GG
hc-A33R-P1 45 80 GCC TGT CTC ACC CAG TGC ATT CTA TAG TCG TCA AAT GTA AAT CCG
hc-A33R-P2 45 80 CGG ATT TAC ATT TGA CGA CTA TAG AAT GCA CTG GGT GAG ACA GGC
*Tm: Primer Melting Temperature
Table 1: Primers of site directed mutagenesis.
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100, 50, 25, 12.5, 6.25, 3.125, 1.56 and 0.00 nM) were injected at a flow 
rate of 80 μL/minute for 180 seconds (240 μL of analyte) to allow their 
association with the bound antibodies. For the dissociation of the TNFα/
antibody complexes, running buffer contain HBS-EP buffer pH 7.4 [0.01 
M HEPES (4-{2-hydroxyethyl-1-piperazineethanesulfonic acid), 0.15 
M NaCl, 3 mM Ethylenediaminetetraacetic acid (EDTA) and 0.005% 
v/v Surfactant P20] (GE Healthcare, USA) was injected at a flow rate 
of 80 μL/minute for 15 minutes. Biosensor matrices were regenerated 
using regeneration buffer (glycine-HCl, pH 1.5) (GE Healthcare, USA). 
Data were processed and fitted to a 1:1 binding model using Biacore 
X100 evaluation software (version 1.0) to determine the binding kinetic 
rate constants, ka (on-rate) and kd (off-rate), and KD (equilibrium 
dissociation constant). We evaluated the likelihood of fitting by the Chi2 
and U-value statistics. The significance threshold of the parameters for 
U-value is<25 as reported elsewhere [23].
TNFα neutralizing activity
TNFα neutralizing activity of the antibodies evaluated on murine 
fibroblast L929 cells (IBG1, KIT, Germany). The cells were grown in 
DMEM medium supplemented with 10% FCS and then seeded at 
200,000 cells/well in 96-well plate overnight at 37°C, triplicate. A series 
of diluted antibody samples were prepared in the presence of a fixed 
concentration of TNFα (10 ng/ml) and actinomycin D (Sigma, USA) for 
60 minutes at 37°C in order to allow neutralization effect of the antibodies 
would occur. After the neutralization, 100 μL of antibody/ TNFα 
mixture was added to each well. The cell plates were further incubated at 
37°C for 24 hours. After that, TNFα-neutralizing activity was estimated 
by a 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
(MTT) (M200, SIGMA) assay. The medium in each well was replaced 
with 200 µl MTT solution (5 µg/ml) and the cell plates were incubated 
for 4 hours at 37°C. Then, the supernatant was removed and tetrazolium 
salts that formed into the living cells were solubilized with 100 µl of 
dimethyl sulphoxide (DMSO) (Sigma-Aldrich). They were shaken for 
10 minutes and the absorbance of each well was measured at 570 nm 
by employing a microplate reader (Biotek, ELx 800, and USA). Results 
achieved as a percent of cell viability were plotted against different 
concentrations (ng/mL) of samples applied by using GraphPad Prism 
7 software.
Structural analysis of binding interactions
The X-ray crystallographic structure of D2E7/TNFα complex 
(3WD5.pdb) was found from Protein Data Bank [24]. The 3WD5.pdb 
was used as an input to Pymol software [25], then the structure was 
mutated by mutagenesis option of Pymol to generating 3D structure 
of lc-A94K antibody and then was energy minimized by Gromacs 
version 4.5.6 [26]. LigPlot was used to evaluating binding pocket of 
the antibody-antigen complexes [27]. Ligplot is a program to produce 
graphic illustrations of protein-ligand interactions including hydrogen-
bond and hydrophobic interaction between the ligand(s) and the main-
chain or side-chain elements of the protein [28].
Statistical analysis
Obtained data were statistically analyzed with GraphPad Prism 7 
software. For in vitro assays, the statistical analyses performed using 
two-way analysis of variance (ANOVA). For all statistical analyses, a 
value of p<0.05 was regarded as statistically significant.
Results
Cloning and expression of the antibodies
The pcDNA3.1 vector with the whole sequence of the D2E7 antibody 
was used to produce D2E7 antibody. For the mutant antibodies, we 
introduced mutations using the four paired primers (Table 1) and site 
directed mutagenesis method [29]. Plasmids encoding the antibodies 
were transfected into HEK293T cells using PEI. The expression of 
the antibodies was confirmed by SDS-PAGE. We used Cinorra (a 
commercial form of D2E7) as a positive control. In non-reducing SDS-
PAGE, we observed a 170 Kilodalton (kDa) protein band for all the 
antibodies (Figure 1A). In reducing SDS-PAGE, two bands at 55 kDa 
and 27 kDa corresponding to the light and heavy chains of the antibodies 
appeared in all samples (Figure 1B), which proved that our expressed 
antibodies behaved exactly the same way as the commercial Cinorra 
antibody do. We harvested the cell culture supernatant of day 1,2 and 3 
and purified them by using protein-A affinity chromatography. Purity 
of the samples was confirmed by SDS-PAGE under both non-reducing 
and reducing condition (Figure 1C and 1D).
Figure 1: SDS-PAGE analysis of non-purified and purified antibodies. (A) Supernatant of the transfected HEK293T cells on a 12% SDS-PAGE gel under non-
reducing condition, (B) supernatant of transfected HEK293Tcells on a 12% SDS-PAGE gel under reducing condition, (C) purified antibodies on a 12% SDS-PAGE 
gel under non-reducing condition, (D) Purified antibodies on a 12% SDS-PAGE gel under reducing condition. Molecular weight marker (Lane1), Cinorra as a positive 
control (Lane 2), D2E7 (Lane 3), lc-A94K (Lane4), lc-N92R (Lane5), lc-A50Y (Lane 6), and hc-A33R (Lane 7).
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Analysis of the secondary structures
To gain further information about possible conformational effects 
of the mutations, secondary structure patterns of the antibodies were 
evaluated by CD spectroscopy in the far-UV range (190-260 nm). The 
CD spectra of the wild and the mutant antibodies possessed an identical 
line shape and reveal a dominance of β-sheet structures (Figure 2). 
Consequently, the data suggest that the mutations have no remarkable 
impact (p>0.05) on the secondary structure of D2E7 (Table 2).
Evaluation of the binding activity of the antibodies
ELISA assay was performed to evaluate ability of the wild and 
the mutant antibodies in binding to recombinant human TNFα by 
determining the concentration value at which the antibodies neutralize 
50% of the antigens (EC50). As demonstrated in Figure 3, the EC50 
of lc-A94K (194.1 ng/ml) and lc-N92R (240.7 ng/ml) increased as 215 
and 173 percent, respectively, in comparison to the EC50 of the wild 
antibody (416.5 ng/ml). The EC50 of lc-A50Y (774.6 ng/ml) and hc-
A33R (917.4 ng/ml) increased in comparison to the native antibody, 
which indicates a lower binding activity of these mutants to TNFα. 
As such, the EC50 values revealed that lc-A94K and lc-N92R models 
significantly improved their binding potency for interaction to TNFα 
(p<0.003) (Figure 3). We candidate these two models for SPR analysis 
and biological assay.
Evaluation of the kinetics affinity of the antibodies
To get further insight into kinetic affinity, SPR spectroscopy was 
performed to measure the thermodynamic affinity and the kinetic 
constant of lc-A94K and lc-N92R antibodies in comparison to the 
native D2E7. In the first step, a fixed concentration of antibodies was 
immobilized on a protein-A sensor chip [30]. The following injection 
of TNFα to this pre-coated surface generated a RU of the SPR signal, 
which is related to the Ka. The Kd was obtained by the dissociation 
of the antigen from the antibody surface during washing, which leads 
to a decrease of the RU signal. Binding constant or KD is the average 
of three experiments. The native antibody KD was as 0.38 nM (Table 
3). Further, it was evident that the A94K mutation caused a 240% 
increase in kinetics affinity of the mutant model compared to the native 
monoclonal antibody (KD=0.16 nM) (Figure 4A and 4B). The increase 
in affinity of lc-A94K for TNFα is due to enhanced on-rates compared 
with native D2E7 antibody (Table 3). This further indicated a significant 
improvement (p<0.005) of the binding affinity of the mutant antibody 
for TNFα. Furthermore, the KD of the lc-N92R mutant (KD=0.37 nM) 
is only a bit different in comparison to wild antibody, which means that 
the mutation had no effect in terms of improving the antigen binding.
Neutralization of TNFα-mediated cytotoxicity by the 
antibodies
We evaluated biological activity of the lc-A94K, lc-N92R and wild 
antibodies to neutralized cytotoxicity effect of TNFα in L929 cells with 
MTT colorimetric assay. The viability of L929 cells that were pre-treated 
with TNFα, analyzed by co-incubation of the cells with each antibody 
in separate experiments. We found lc-A94K and native D2E7 antibody 
could efficiently neutralize cytotoxicity in L929 cells through a dose-
dependent manner, with IC50 of 450 ng/ml and 145 ng/ml, respectively. 
As shown in Figure 5, lc-A94K antibody neutralizes cytotoxicity of the 
cells significantly three fold stronger than the native D2E7 (p<0.001). 
These results, taken together, confirmed that single point mutation 
of ALA to LYS in the lc-CDR3 D2E7 increase binding activity of the 
antibody for TNFα results in improvement of its potency to neutralize 
cytotoxicity effect of TNFα. The IC50 of lc-N92R was about 470 ng/ml 
that means the biological activity of the mutant decreased in contrast 
to wild antibody (Figure 5).
Binding interaction analysis of antibodies in complex with 
TNFα
The 3D structure of D2E7/TNFα complex and lc-A94K/TNFα 
complex were applied as an input for Ligplot software. The program 
visualized hydrogen and hydrophobic interactions at the binding 
pocket of the complexes. By analyzing the antibody-antigen complexes, 
we found that mutating of ALA to LYS in the lc-CDR3 of D2E7 
antibody leaded to generating new hydrogen bonds and hydrophobic 
interactions with the epitopes of TNFα. The data showed ARG90 and 
Antibodies Helix Antiparallel Parallel Turn Others Anti 1 (Left twisted) Anti 2 (Relaxed) Anti (Right-twisted)
Wild 0 46 7.7 10.3 36 7.6 19 19.4
lc-A94K 0 44.9 7.9 10.9 36.3 7.1 18.5 19.3
hc-A33R 0 46.1 7.8 10.6 35.5 7.5 19.3 19.3
lc-A50Y 0.5 44.7 8.1 11 35.7 7.3 17.8 19.6
lc-N92R 0 46.4 6.4 11.1 36.1 7.5 19.1 19.8
Table 2: Quantitative analysis of the secondary structure of the wild and mutant antibodies by CD spectroscopy.
Figure 2: Evaluation of the secondary structure of the wild and mutant antibodies by CD spectroscopy. All CD spectra possess an identical line-shape, which proves 
that the mutations did not influence the secondary structure of the antibody (p>0.05).
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ARG93 from wild antibody are participating in the three hydrogen 
bonds with PRO20, GLN21 and ALA22 from TNFα (Figure 6A). 
Remarkably, in the binding pocket of lc-A94K/TNFα complex, ARG90, 
ARG93 and ARG94 from lc-A94K are taking part in the six hydrogen 
bonds with GLN21, ALA22, PRO20, GLU23, and ALA145 from TNFα 
(Figure 6B).
Discussion
Adalimumab is a human recombinant IgG1 isotype directed 
against the soluble and cell-bound forms of TNFα [31]. Although 
the antibody has already high affinity but patients require a high 
dosage of the antibody per single administration that such dosage can 
intensify different side effects [32-34]. Various studies revealed greater 
binding affinity, particularly for soluble cytokines, often correlates 
with improved biological activity, resulting in decrease dosage and 
potentially fewer adverse events [35,36]. Thus CDRs engineering of the 
antibody is a promising starting point for increasing its binding affinity 
Figure 3: Evaluation of the binding affinity of the wild and mutant antibodies by ELISA. EC50 of the lc-A94K and lc-N92R is lower than the native D2E7, p<0.003. Data 
are represented as mean ± standard deviation (SD).
Figure 4: Binding sonograms of the wild and lc-A94K antibody with TNFα. (A) and (B) represent binding of the wild and lc-A94K to TNFα, respectively. For each 
experiment, different concentration of TNFα were loaded on the chip (from 20 to 200 second) to allow their association with the bound antibodies (5 µg/mL). Then, 
running buffer injected for 15 min to dissociate antigens from antibodies. The RU is proportional to the concentration of TNFα binding to each antibodies which 
decorated on the chip. Ka, Kd, and KD are average of three experiments, p<0.005.
Figure 5: Neutralization of TNFα-mediated cytotoxicity in L929 cells by wild, 
lc-A94K and lc-N92R antibodies. Data are represented as mean ± SD and 
asterisks show the statistical level of significance between neutralization of the 
TNFα by different the antibodies (***p<0.001).
Antibody Ka (M-1S-1) Kd (S-1) *KD (M) ΨU-value
Wild 3.6 E+5 (1.1E+05) 1.4 E-4 (3.2E-7) 3.8E-10 (2.2E-11) 12
lc-A94K 6.8 E+5 (1.0 E+05) 1.1 E-4 (2.1E-7) 1.6E-10 (1.4E-11) 3
lc-N92R 4.9 E+5 (1.3 E+05) 1.8 E-4 (4.2E-7) 3.7E-10 (1.7E-11) 12
*Binding constants (KD) are the average of three experiments (SD in parenthesis).
ΨU-value significant threshold is<25. 
Table 3: Affinity and binding kinetic parameters of wild and mutant antibodies.
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to TNFα regarding to achieve greater biological activity and clinical 
efficiency. With similar reasoning, we have applied a computational 
structural approach to making D2E7 mutants with improved binding 
affinity to TNFα. In the current study, we cloned and expressed lc-
A94K, lc-N92R, lc-A50Y, hc-A33R mutant models and D2E7 antibody 
in HEK293T cell line. We identified that the EC50 and KD of the lc-
A94K mutant were significantly increased in comparison to the EC50 
and KD of the native antibody. Moreover, our data revealed that lc-
A94K antibody could effectively neutralize the cytotoxicity effect of 
TNFα in L929 cells with higher potency than the native antibody.
In the present study, we aimed to improve the binding affinity of 
D2E7 to its ligand by introducing a minimum number of mutations 
(single mutations) in CDR sequences while preserving the native 
structure of the antibody as much as possible. We found that the 
secondary structures of all mutants are consistent with the structures 
of wild antibody (Table 2). These data showed the mutations occurred 
without affecting the secondary structures of the mutant antibodies 
thus the principle structure of D2E7 have been precisely conserved at 
the mutant models. Rajpal et al. engineered D2E7 CDRs by introducing 
more than ten point mutations in order to increase binding affinity [8]. 
In another similar study, Votsmeie et al. used a display-based approach 
in order to enhance the affinity of D2E7 antibody [18]. Although the 
two groups had been successful to significantly improve the D2E7 
affinity, recent studies revealed that primary problem by introducing 
extensive mutations during affinity maturation is the modification of 
antibody basic structure that would translate to the adverse effects on 
their specificity and stability [37].
It is also notable that lc-A94K revealed an enhanced binding 
activity and kinetic affinity nearly 215 and 240 percent respectively 
in comparison to the wild antibody. Moreover, biological activity of 
the antibody improved three fold higher than the native antibody. 
Interestingly, the mutant models with the greatest efficiency harbored 
a single point mutation that was modified with a charged amino 
acid residue. It was reported that the affinity of an antibody against 
its ligand was enhanced by introducing charged amino acid residues 
into the CDRs of an antibody [38]. From a structural point of view 
on the binding site of lc-A94k with its antigen, we found mutation of 
ALA to LYS in residue94 of lc-CDR3 D2E7 enhanced hydrogen and 
hydrophobic interactions at the binding site of the antibody. Thus 
improvement of the non-polar bonds could potentially enhance 
energetically interactions at the binding pocket of lc-A94K/TNFα. Peng 
et al. revealed that energetically critical epitope factors have mainly 
consisted of hydrogen and hydrophobic bonds donors/acceptors. The 
physicochemical features are mainly important portions for paratopes 
of an antibody to recognizing an antigens [39]. Erijman et al. found 
that hydrogen (H) interactions are an important contributor to protein 
stability, folding and binding. They reported that although the energy 
of one H bond is relatively small, a large number of H bonds in proteins 
help them to play a significant role in protein-protein interaction 
energy [40].
In conclusion, we were enabled to identify lc-A94K as a mutant 
model of D2E7 antibody that contributed to an increase in binding 
affinity and biological activity of the antibody toward TNFα. 
Importantly, it should be pointed out that further in vivo and clinical 
assays are needed to compare therapeutic efficacy of lc-A94K with the 
original form of the antibody. The other mutant models showed no 
improvement in binding and potency to the ligand in the experimental 
assays. This may indicate that the affinity maturation is still a multipart 
complex process.
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